|
1
|
Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang CY, Yuan WG, He P, Lei JH and Wang CX: Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Higashi T, Friedman SL and Hoshida Y: Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schuppan D and Kim YO: Evolving therapies for liver fibrosis. J Clin Invest. 123:1887–1901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hong F, Chou H, Fiel MI and Friedman SL: Antifibrotic activity of sorafenib in experimental hepatic fibrosis: Refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci. 58:257–264. 2013.PubMed/NCBI
|
|
6
|
Deng YR, Ma HD, Tsuneyama K, Yang W, Wang YH, Lu FT, Liu CH, Liu P, He XS, Diehl AM, et al: STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimmun. 46:25–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hennenberg M, Trebicka J, Kohistani Z, Stark C, Nischalke HD, Krämer B, Körner C, Klein S, Granzow M, Fischer HP, et al: Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest. 91:241–251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
ENCODE Project Consortium, ; Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, et al: Identification and analysis of functional elements in 1% of the human genome by ENCODE pilot project. Nature. 447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim YA, Park KK and Lee SJ: lncRNAs Act as a link between chronic liver disease and hepatocellular carcinoma. Int J Mol Sci. 21:28832020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanson A, Wilhelmsen D and DiStefano JK: The role of long non-coding RNAs (lncRNAs) in the development and progression of fibrosis associated with nonalcoholic fatty liver disease (NAFLD). Noncoding RNA. 4:182018.PubMed/NCBI
|
|
11
|
Li X and Liu R: Long non-coding RNA H19 in the liver-gut axis: A diagnostic marker and therapeutic target for liver diseases. Exp Mol Pathol. 115:1044722020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leti F, Legendre C, Still CD, Chu X, Petrick A, Gerhard GS and DiStefano JK: Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Transl Res. 190:25–39.e21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He Y, Wu YT, Huang C, Meng XM, Ma TT, Wu BM, Xu FY, Zhang L, Lv XW and Li J: Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim Biophys Acta. 1842:2204–2215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsuchida T and Friedman SL: Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 14:397–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu F, Geng W, Dong P, Huang Z and Zheng J: lncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death Dis. 9:10142018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen MJ, Wang XG, Sun ZX and Liu XC: Diagnostic value of lncRNA-MEG3 as a serum biomarker in patients with hepatitis B complicated with liver fibrosis. Eur Rev Med Pharmacol Sci. 23:4360–4367. 2019.PubMed/NCBI
|
|
17
|
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu F, Lu Z, Cai J, Huang K, Chen B, Li G, Dong P and Zheng J: MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis. Cell Cycle. 14:3885–3896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kong Y, Huang T, Zhang H, Zhang Q, Ren J, Guo X, Fan H and Liu L: The lncRNA NEAT1/miR-29b/Atg9a axis regulates IGFBPrP1-induced autophagy and activation of mouse hepatic stellate cells. Life Sci. 237:1169022019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sulaiman SA, Muhsin NIA and Jamal R: Regulatory Non-coding RNAs Network in Non-alcoholic fatty liver disease. Front Physiol. 10:2792019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, et al: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 43:1317–1325. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li C, Liu YF, Huang C, Chen YX, Xu CY and Chen Y: Long noncoding RNA NEAT1 sponges miR-129 to modulate renal fibrosis by regulation of collagen type I. Am J Physiol Renal Physiol. 319:F93–F105. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Practice Res Clin Gastroenterol. 25:195–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Men R, Wen M, Zhao M, Dan X, Yang Z, Wu W, Wang MH, Liu X and Yang L: MircoRNA-145 promotes activation of hepatic stellate cells via targeting krüppel-like factor 4. Sci Rep. 7:404682017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He Z, Yang D, Fan X, Zhang M, Li Y, Gu X and Yang M: The roles and mechanisms of lncRNAs in liver fibrosis. Int J Mol Sci. 21:14822020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chi Y, Wang D, Wang J, Yu W and Yang J: Long Non-Coding RNA in the pathogenesis of cancers. Cells1. 8:10152019. View Article : Google Scholar
|
|
28
|
Zhang W, Xu W, Feng Y, Feng Y and Zhou X: Non-coding RNA involvement in the pathogenesis of diabetic cardiomyopathy. J Cell Mol Med. 23:5859–5867. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y and Klibanski A: Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: Isoform structure, expression, and functions. Endocrinology. 151:939–947. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, Kreipe H and Lehmann U: Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One. 7:e494622012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He Y, Luo Y, Liang B, Ye L, Lu G and He W: Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget. 8:73282–73295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cui X, Jing X, Long C, Tian J and Zhu J: Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: A meta-analysis. Oncotarget. 8:19049–19056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang CY, Yu MS, Li X, Zhang Z, Han CR and Yan B: Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol. 39:10104283177013112017.PubMed/NCBI
|
|
34
|
Zhang L, Yang Z, Trottier J, Barbier O and Wang L: Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay. Hepatology. 65:604–615. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Jiang X, Duan L and Wang W: Long non-coding RNA MEG3 impacts diabetic nephropathy progression through sponging miR-145. Am J Transl Res. 11:6691–6698. 2019.PubMed/NCBI
|
|
36
|
Chen Y, Zhang Z, Zhu D, Zhao W and Li F: Long non-coding RNA MEG3 serves as a ceRNA for microRNA-145 to induce apoptosis of AC16 cardiomyocytes under high glucose condition. Biosci Rep. 39:BSR201904442019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang S, Cui H, Xie N, Icyuz M, Banerjee S, Antony VB, Abraham E, Thannickal VJ and Liu G: miR-145 regulates myofibroblast differentiation and lung fibrosis. FASEB J. 27:2382–2391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Men R, Wen M, Zhao M, Dan X, Yang Z, Wu W, Wang MH, Liu X and Yang L: MircoRNA-145 promotes activation of hepatic stellate cells via targeting krüppel-like factor 4. Sci Rep. 7:404682017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ly T, Riedel L, Fischer B, Schmidt V, Hendig D, Distler J, Kuhn J, Knabbe C and Faust I: microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. Biochem Biophys Res Commun. 523:1001–1006. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zeybel M, Hardy T, Wong Y, Mathers JC, Fox CR, Gackowska A, Oakley F, Burt AD, Wilson CL, Anstee QM, et al: Multigenera-tional epigenetic adaptation of the hepatic wound-healing response. Nat Med. 18:1369–1377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu X, Xu J, Rosenthal S, Zhang LJ, McCubbin R, Meshgin N, Shang L, Koyama Y, Ma HY, Sharma S, et al: Identification of Lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology. 158:1728–1744.e14. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Park JK, Ki MR, Lee HR, Hong IH, Ji AR, Ishigami A, Park SI, Kim JM, Chung HY, Yoo SE and Jeong KS: Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice. Hepatology. 51:1766–1777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tao L, Wu L, Zhang W, Ma WT, Yang GY, Zhang J, Xue DY, Chen B and Liu C: Peroxisome proliferator-activated receptor γ inhibits hepatic stellate cell activation regulated by miR-942 in chronic hepatitis B liver fibrosis. Life Sci. 253:1175722020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu D, Lyu L, Shen P, Wang J, Chen J, Sun X, Chen L, Zhang L, Zhou Q and Duan Y: rSjP40 protein promotes PPARγ expression in LX-2 cells through microRNA-27b. FASEB J. 32:4798–4803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, Satishchandran A and Szabo G: The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 64:1378–1387. 2016. View Article : Google Scholar : PubMed/NCBI
|
